Pas encore inscrit ? Creez un Overblog!

Créer mon blog

Dr. Ari Massoudi

Dr. Ari Massoudi

Scientist turned Consultant. Interested by Science, Technology, Entrepreneurship, Startup, Innovation, Strategy, Marketing, Business Development, Fundraising ...

Ses blogs

Strategy of Innovation

Strategy of Innovation

Knowledge + Imagination + Entrepreneurship = Innovation
Dr. Ari Massoudi Dr. Ari Massoudi
Articles : 394
Depuis : 19/01/2009
Categorie : Technologie & Science

Articles à découvrir

Cancer Contagieux : Nouvelle Arme Biologique ?

Cancer Contagieux : Nouvelle Arme Biologique ?

Si vous ne deviez lire qu'un livre sur le cancer, je vous recommande "L'abominable secret du cancer" du Dr. Frédéric Thomas, biologiste de l'évolution, directeur de recherche au CNRS. Sur les bancs de la fac, j'avais appris que le cancer était une maladie de cause génétique - mutations primaires touchant les gènes qui contrôlent la division
Comment Utiliser le Moutonisme pour Innover

Comment Utiliser le Moutonisme pour Innover

A visionner jusqu'à la fin de la vidéo pour comprendre ! PDF Préambule : quand il s’agit de nouveauté (idée, produit matériel ou immatériel - service, prestation ... -), la majorité des gens sont incapables de décider s’ils aiment cette nouveauté, si elle leur convient, leur est utile … Ils en sont INCAPABLES. Cibler une niche pour
ForeverYoung: The Ultimate Stem Cells Biotechnology Startup!

ForeverYoung: The Ultimate Stem Cells Biotechnology Startup!

Sample of human urine containing living kidney cells that can be transformed into iPS cells. (credit: Wikipedia) ForeverYoung promises to save your life with your own fountain of youth! ForeverYoung is a bold biotech startup offering you to produce your own induced-Pluripotent Stem cells (iPS cells*) and to bank them for you until you need them if
FUNDRAISING FOR BIO-PHARMA STARTUPS AND PHASE-I CLINICAL TRIALS

FUNDRAISING FOR BIO-PHARMA STARTUPS AND PHASE-I CLINICAL TRIALS

Many biotech-pharma startups that have developed a promising new drug can not test it into a phase-I clinical trial because of the lake of money. Do you lead an Academic Research Team in life or medical sciences? Are you the CEO or CSO of a pharma/biotech startup? Do you have a new drug (chemical drug or biotechnology) to evaluate in a phase-I clin
Crowdfunding for Academic Research and Technology Transfer

Crowdfunding for Academic Research and Technology Transfer

A short introduction to an alternative way to fund scientific research and technology transfer into startups. Crowdfunding for Academic Research and Technology Transfer de Ari Massoudi Introduction to Crowdfunding from Ari Massoudi
Post-Coronavirus Crisis for Contract Research Organizations

Post-Coronavirus Crisis for Contract Research Organizations

Dear Contract Research Organizations, We can help your Clients to fund their clinical research projects and therefore to be able to hire you and your services! Let's prepare together and right-now the Coronavirus post-Crisis! Contact Ari to discuss further => https://www.linkedin.com/in/arimassoudi/
Innovation, Revolution, Disruption versus Nouveauté / Novelty !

Innovation, Revolution, Disruption versus Nouveauté / Novelty !

Startupers, arrêtez d'utiliser le mot "innovation" (et encore moins "révolutionnaire" ou "disruptif") pour qualifier vos solutions/produits car le mot innovation va vous aveugler ! Une innovation se définit par "une nouveauté qui a diffusée dans la Société" cad un succès business pour faire simple. Le terme innovation contient en lui la not
Fundraising for Phase-I Clinical Trials

Fundraising for Phase-I Clinical Trials

... because we believe what you do is precious for Humanity! Do you lead an Academic Research Team in life or medical sciences? Are you the CEO or CSO of a pharma/biotech startups? Do you have a new treatment (chemical drug or biotechnology) to evaluate in a phase-I clinical trial for which you need a funding? Is the uncertainty of institutional fu
The Pharma Industry Holy Grail

The Pharma Industry Holy Grail

The discovery of biomarkers specifically related to the injury of an organ (such as kidney, liver or vascular system) and detectable as early as the phase-1 or even in pre-clinical studies is the greatest challenge for the pharmaceutical industry (including Academic labs and startups). In Western countries, every year, 100,000 to 500,000 patients a